QLT Announces Third Quarter 2014 Results VANCOUVER, British

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
QLT Announces Third Quarter 2014 Results

VANCOUVER, British Columbia, Oct. 28, 2014 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq: QLTI ) (TSX: QLT ) ("QLT" or the "Company") is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. The Company reported financial results today for the third quarter ended September 30, 2014. Unless otherwise specified, all amounts are reported in U.S. dollars and in accordance with U.S. GAAP.

2014 THIRD QUARTER FINANCIAL RESULTS

QLT Expenses

Research and Development (R&D) expenses relate to QLT's synthetic retinoid program. During the third quarter of 2014, QLT incurred R&D expenses of $2.8 million compared to $5.2 million for the same period in 2013. The net $2.4 million decrease was primarily due to higher costs incurred in 2013 related to certain toxicity studies, which commenced in the second half of 2013, and our Leber Congenital Amaurosis and Retinitis Pigmentosa Phase Ib retreatment study, which was substantially completed in 2013. The period-over-period decrease in R&D expenditures was further positively affected by savings realized in 2014 related to the continuing impact of our 2012 workforce reduction and other restructuring activities.

During the third quarter of 2014, Selling, General and Administrative (SG&A) expenses were $2.4 million compared to $1.7 million for the same period in 2013. The net $0.7 million increase in SG&A expenses was primarily due to $1.2 million of consulting and transaction fees incurred in connection with the proposed merger with Auxilium Pharmaceuticals, Inc. ("Auxilium") described below. These costs were partially offset by net overall savings realized in 2014 related to the continuing impact of our 2012 workforce reduction and other restructuring activities.

Operating Losses and Loss per Share

The operating loss for the third quarter of 2014 was $5.4 million compared to $7.5 million for the same period in 2013. The net $2.1 million decrease in operating losses is primarily due to lower R&D and restructuring expenses. These cost savings were partially offset by $1.2 million of consulting and transaction fees incurred during the period in connection with the proposed merger with Auxilium.

Loss per share from continuing operations was $0.10 in the third quarter of 2014 compared to $0.14 in the same period in 2013. The decrease in loss per share is due to the same factors described above, as well as a $0.4 million income tax recovery recorded in connection with a decrease in our provision for uncertain tax positions due to the expiration of the statute of limitations.

Cash and Cash Equivalents

As at September 30, 2014, the Company's consolidated cash and cash equivalents were $137.8 million compared to $118.5 million of cash and cash equivalents at the end of 2013. The increase was primarily due to $38.1 million of proceeds received from Tolmar in connection with the Eligard ® related contingent consideration, which was partially offset by cash used in operating activities.

Termination of Merger Agreement with Auxilium

As previously reported, on October 8, 2014, Auxilium terminated the Agreement and Plan of Merger dated June 25, 2014 (the "Merger Agreement") among QLT, Auxilium, QLT Holding Corp. and QLT Acquisition Corp. The Merger Agreement contemplated a business combination whereby Auxilium would have become an indirect wholly-owned subsidiary of QLT (the "Combined Company") and Auxilium's stockholders would have received common shares representing approximately 76% of the Combined Company. On October 8, 2014, Auxilium terminated the Merger Agreement after receiving from Endo International plc what Auxilium's board of directors determined to be a "superior proposal" to acquire all of the issued and outstanding shares of Auxilium. In accordance with the termination provisions of the Merger Agreement, on October 9, 2014, Auxilium paid QLT a termination fee of $28.4 million. On October 22, 2014, pursuant to the terms of our financial advisory services agreement with Credit Suisse, our financial advisor in the transaction, we paid Credit Suisse a fee of $5.7 million in connection with the termination of the Merger Agreement.

Passive Foreign Investment Company

The Company believes that it was classified as a Passive Foreign Investment Company (PFIC) for 2008 through 2013, and that it may be classified as a PFIC in 2014, which could have adverse tax consequences for U.S. shareholders. Please refer to our 2013 Annual Report on Form 10-K for additional information.

QLT Inc. - Financial Highlights
         
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
In accordance with United Stated generally accepted accounting principles
(Unaudited)
  Three months ended Nine months ended
  September 30, September 30,
(In thousands of U.S. dollars except share and per share amounts) 2014 2013 2014 2013
Expenses        
Research and development  $ 2,792  $ 5,243  $ 11,684  $ 13,715
Selling, general and administrative 2,388  1,676 8,642  5,568
Depreciation 222  230 680  717
Restructuring charges  --  354 744  1,847
  5,402  7,503 21,750  21,847
         
Operating loss  (5,402)  (7,503)  (21,750)  (21,847)
         
Investment and other (expenses) income        
Net foreign exchange losses  --  (54)  (74)  (36)
Interest income 27  39 80  175
Fair value change in contingent consideration  --  71 1,466  1,904
Other  17  64 115  100
   44  120 1,587  2,143
         
Loss from continuing operations before income taxes  (5,358)  (7,383)  (20,163)  (19,704)
         
Recovery of (provision for) income taxes 432  (109) 194  (434)
Loss from continuing operations  (4,927)  (7,492)  (19,969)  (20,138)
         
(Loss) income from discontinued operations, net of income taxes  (6)  96  (63)  116
         
Net loss and comprehensive loss $ (4,932)  $ (7,396) ($20,032)  $ (20,022)
         
Basic and diluted net loss per common share        
Continuing operations ($0.10) ($0.15) ($0.39) ($0.40)
Discontinued operations  (0.00)  0.00  (0.00)  0.00
Net loss per common share ($0.10) ($0.14) ($0.39) ($0.39)
         
Weighted average number of common shares outstanding (in thousands)        
Basic and diluted  51,151  51,082  51,105  50,851
         
         
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands of U.S. dollars) September 30, 2014 December 31, 2013
ASSETS    
Current assets    
Cash and cash equivalents  $ 137,828  $ 118,521
Accounts receivable, net of allowances for doubtful accounts  4,440  4,590
Contingent consideration - current  --  36,582
Income taxes receivable  68  77
Deferred income tax assets - current  --  191
Prepaid and other assets  787  1,863
Total current assets  143,123  161,824
     
Property, plant and equipment  1,211  1,866
Deferred income tax assets - non-current  --  177
Total assets  144,334  163,867
     
LIABILITIES    
Current liabilities    
Accounts payable  $ 2,405  $ 2,609
Accrued liabilities 1,283  1,498
Accrued restructuring charge 0  130
Total current liabilities 3,688  4,237
     
Uncertain tax position liabilities 398  1,846
Total liabilities 4,086  6,083
     
SHAREHOLDERS' EQUITY    
Share capital    
Authorized    
500,000,000 common shares without par value    
5,000,000 first preference shares without par value, issuable in series    
Issued and outstanding common shares  $ 466,979  $ 466,229
March 31, 2014 – 51,081,878 shares    
December 31, 2013 – 51,081,878 shares    
Additional paid-in capital 97,590  95,844
Accumulated deficit  (527,290)  (507,258)
Accumulated other comprehensive income 102,969  102,969
Total shareholders' equity 140,248  157,784
Total shareholders' equity and liabilities  $ 144,334  $ 163,867
     

About QLT

QLT is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. We are focused on developing our synthetic retinoid program for the treatment of certain inherited retinal diseases.

QLT's head office is based in Vancouver, Canada and the Company is publicly traded on NASDAQ Stock Market (symbol: QLTI) and the Toronto Stock Exchange (symbol: QLT). For more information about the Company's products and developments, please visit our web site at www.qltinc.com .  

Visudyne ® is a registered trademark of Novartis AG

Eligard ® is a registered trademark of Tolmar Therapeutics, Inc.

Certain statements in this press release constitute "forward-looking statements" of QLT within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements include, but are not limited to: statements concerning our PFIC status; and statements which contain language such as: "assuming," "prospects," "goal," "future," "projects," "potential," "believes," "expects," "hopes," and "outlook." Forward-looking statements are predictions only which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed in such statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: the Company's future operating results are uncertain and likely to fluctuate; currency fluctuations; the risk that we may not receive any or as much additional contingent consideration as we might expect under our agreements with respect to the sale of Visudyne ® and the PPDS Technology; the risk that we will be treated as a Passive Foreign Investment Company (PFIC) in 2014 and future years; risks and uncertainties concerning the impact that QLT's success or failure in pursuing future strategic initiatives will have on the market price of our securities; risks resulting from the potential loss of key personnel; uncertainties relating to our development plans, timing and results of the clinical development and commercialization of our products and technologies; assumptions related to continued enrollment trends, efforts and success, and the associated costs of these programs; outcomes for our clinical trials may not be favorable or may be less favorable than interim/preliminary results and/or previous trials; there may be varying interpretations of data produced by one or more of our clinical trials; risks and uncertainties associated with the safety and effectiveness of our technology; the timing, expense and uncertainty associated with the regulatory approval process for products to advance through development stages; risks and uncertainties related to the scope, validity, and enforceability of our intellectual property rights and the impact of patents and other intellectual property of third parties; and general economic conditions and other factors described in detail in QLT's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are based on the current expectations of QLT and QLT does not assume any obligation to update such information to reflect later events or developments except as required by law.

This press release also contains "forward looking information" that constitutes "financial outlooks" within the meaning of applicable Canadian securities laws. This information is provided to give investors general guidance on management's current expectations of certain factors affecting our business, including our financial results. Given the uncertainties, assumptions and risk factors associated with this type of information, including those described above, investors are cautioned that the information may not be appropriate for other purposes.

QLT Inc. Contacts: Investor & Media Relations Andrea Rabney or David Pitts Argot Partners 212-600-1902

Scroll down for more posts ▼

Top 10 Most Recent News Articles

24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 15

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading
SecureSpace Plants a Fifth Flag in Miami Beach Storage

Updated Category News Views 111

A small box on Alton Road may carry outsized weight Miami Beach does not hand out cheap, easy real estate wins, which is why SecureSpace's opening at 633 Alton Road deserves a closer look than its modest footprint might suggest. The newly rebranded SecureSpace Miami Beach facility has 18,358 square feet of traditional storage and locker space spread across 536 units, plus...

Continue Reading
Workday’s EU Cloud Move Raises the Sovereignty Bar Again

Updated Category News Views 27

Europe’s sovereignty squeeze just got a lot more concrete for Workday. The company is taking its EU Sovereign Cloud beyond the usual data-residency talking points by planning an Ireland-based operating company, European leadership, and governance intended to keep decisions on the service and customer data inside Europe. For a platform sitting underneath payroll, HR...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 190

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Autoliv's Omni Safety Award Is a Promising Early Signal

Updated Category News Views 34

Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 141

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 114

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
Charter’s $1.5 Billion Tender Tests Debt Discipline

Updated Category News Views 247

Debt cleanup arrives with a hard ceiling Eight far-dated bond issues just got a very specific invitation from Charter Communications: hand them over for cash, but do not expect the company to write a blank check. Charter set final pricing on November 17 for tender offers covering up to $1.5 billion in aggregate consideration, excluding accrued interest and deal expenses....

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 17

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 81

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading

Top 5 Most Recently Viewed Articles

Lexicon Pharmaceuticals Unveils Q3 Financials and Future Plans

Updated Category News Views 138

Third Quarter Financial Highlights of Lexicon Pharmaceuticals Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) has disclosed its financial performance for the third quarter of 2025, highlighting significant revenue increases attributed primarily to strategic licensing agreements and product sales. Strategic Partnerships and Revenue Growth In an impressive leap, Lexicon's...

Continue Reading
Growing Innovations in Robotic Dentistry to 2034 and Beyond

Updated Category News Views 178

The Rise of Robotic Dentistry and Its Market Growth The shift towards technological integration in the healthcare sector has begun a revolutionary transformation in dental care. The robotic dentistry market is anticipated to grow significantly, projected to increase from USD 617.39 million in 2024 to an approximate USD 2.24 billion by 2034. This acceleration is based on a...

Continue Reading
Chipotle Lawsuit Update: Key Actions for Shareholders

Updated Category News Views 126

Important Information for Chipotle Shareholders Shareholders of Chipotle Mexican Grill, Inc. (NYSE: CMG) are being advised about an ongoing class action lawsuit that could impact their investments. It is vital for all affected shareholders to take note of critical deadlines and actions they need to undertake to ensure their rights and potential recoveries are protected....

Continue Reading
Quisitive Technology Solutions Reports Q2 2024 Financial Results

Updated Category News Views 144

Quisitive Reports Second Quarter 2024 Financial Results Quisitive Technology Solutions Inc. (“Quisitive” or the “Company”) (TSXV: QUIS, OTCQX: QUISF), a leading provider of Microsoft Cloud and AI solutions, has announced its financial results for the second quarter ending June 30, 2024. Management Commentary Quisitive's CEO, Mike Reinhart, commented, “The first...

Continue Reading
Natural Grocers Reports Strong Fiscal 2024 Performance

Updated Category News Views 231

Natural Grocers by Vitamin Cottage Sees Remarkable Growth in Fiscal 2024 Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) has unveiled its financial results for the fourth quarter and full year of fiscal 2024. The report highlights significant sales and earnings achievements, showcasing the company’s robust performance in a competitive grocery market. Exceptional...

Continue Reading